The Role of CD62L in T Cell Activity Against Tumors
Author Information
Author(s): Yang Shicheng, Liu Fang, Qiong J. Rosenberg, Steven A. Morgan, Richard A. Morgan
Primary Institution: Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
Hypothesis
The shedding of CD62L regulates the acquisition of lytic activity in human tumor-reactive T lymphocytes.
Conclusion
The shedding of CD62L from T cells is associated with increased lytic activity against tumors.
Supporting Evidence
- The loss of CD62L expression was observed in T cells after encountering tumor antigens.
- CD107a expression was primarily detected in T cells that had shed CD62L.
- Introduction of a shedding-resistant mutant of CD62L reduced T cell lytic activity.
Takeaway
When T cells fight tumors, they lose a marker called CD62L, which helps them become better at killing cancer cells.
Methodology
The study used in vitro generated anti-tumor T cells and melanoma lines to evaluate CD62L shedding and CD107a expression as markers of lytic activity.
Participant Demographics
The study involved healthy donors and metastatic melanoma patients.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website